Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains.

Ramos-Sevillano E, Rodríguez-Sosa C, Cafini F, Giménez MJ, Navarro A, Sevillano D, Alou L, García E, Aguilar L, Yuste J.

PLoS One. 2012;7(9):e44135. doi: 10.1371/journal.pone.0044135. Epub 2012 Sep 5.

2.

Macrolides and β-lactam antibiotics enhance C3b deposition on the surface of multidrug-resistant Streptococcus pneumoniae strains by a LytA autolysin-dependent mechanism.

Ramos-Sevillano E, Rodríguez-Sosa C, Díez-Martínez R, Giménez MJ, Olmedillas E, García P, García E, Aguilar L, Yuste J.

Antimicrob Agents Chemother. 2012 Nov;56(11):5534-40. doi: 10.1128/AAC.01470-12. Epub 2012 Aug 13.

3.

Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model.

Cafini F, Yuste J, Giménez MJ, Sevillano D, Aguilar L, Alou L, Ramos-Sevillano E, Torrico M, González N, García E, Coronel P, Prieto J.

PLoS One. 2010 Aug 10;5(8):e12041. doi: 10.1371/journal.pone.0012041.

4.

In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.

Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ.

Diagn Microbiol Infect Dis. 2008 Oct;62(2):210-5. doi: 10.1016/j.diagmicrobio.2008.06.007. Epub 2008 Aug 20.

PMID:
18715733
5.

Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway.

Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, Hyams C, Baxendale HE, Goldblatt F, Botto M, Brown JS.

Infect Immun. 2008 Aug;76(8):3761-70. doi: 10.1128/IAI.00291-08. Epub 2008 Jun 9.

6.

Biofilm formation avoids complement immunity and phagocytosis of Streptococcus pneumoniae.

Domenech M, Ramos-Sevillano E, García E, Moscoso M, Yuste J.

Infect Immun. 2013 Jul;81(7):2606-15. doi: 10.1128/IAI.00491-13. Epub 2013 May 6.

8.

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

Kosowska-Shick K, McGhee PL, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):1670-7. doi: 10.1128/AAC.00019-10. Epub 2010 Mar 1.

9.

Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae.

Yuste J, Botto M, Bottoms SE, Brown JS.

PLoS Pathog. 2007 Sep 28;3(9):1208-19.

10.

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.

McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, Beall B, Whitney CG, Klugman KP.

Antimicrob Agents Chemother. 2009 Feb;53(2):552-6. doi: 10.1128/AAC.01324-08. Epub 2008 Nov 17.

11.

Effects of Streptococcus pneumoniae strain background on complement resistance.

Hyams C, Opel S, Hanage W, Yuste J, Bax K, Henriques-Normark B, Spratt BG, Brown JS.

PLoS One. 2011;6(10):e24581. doi: 10.1371/journal.pone.0024581. Epub 2011 Oct 13.

12.

Defective binding of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma.

Cheson BD, Walker HS, Heath ME, Gobel RJ, Janatova J.

Blood. 1984 Apr;63(4):949-57.

13.

Beta-lactam activity against resistant pneumococcal strains is enhanced by the immune system.

Casal J, Giménez MJ, Aguilar L, Yuste J, Jado I, Tarragó D, Fenoll A.

J Antimicrob Chemother. 2002 Dec;50 Suppl S2:83-6. Review.

14.

Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ.

Antimicrob Agents Chemother. 2012 May;56(5):2691-5. doi: 10.1128/AAC.06185-11. Epub 2012 Feb 21.

15.

In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.

Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.

Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. Epub 2012 Apr 21.

PMID:
22521692
16.

In-vitro activity of cefditoren against clinical isolates of penicillin-susceptible and resistant strains of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis.

Fernández-Roblas R, López JC, Ramos JM, Gimeno M, Coronel P, Soriano F.

J Antimicrob Chemother. 1996 May;37(5):1038-9. No abstract available.

17.
18.

Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.

Gums JG, Boatwright DW, Camblin M, Halstead DC, Jones ME, Sanderson R.

Ann Pharmacother. 2008 Jan;42(1):71-9. Epub 2007 Dec 19. Review.

PMID:
18094350
19.

In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren.

Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF.

Diagn Microbiol Infect Dis. 2002 Jan;42(1):59-64.

PMID:
11821173
20.

In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.

Giron KP, Gross ME, Musher DM, Williams TW Jr, Tharappel RA.

Antimicrob Agents Chemother. 1995 Dec;39(12):2798-800.

Items per page

Supplemental Content

Write to the Help Desk